WebOct 1, 2024 · DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. CD40 and 4-1BB were selected as targets to enhance both dendritic cell (DC) and antigen-dependent T-cell activation, using an inert DuoBody format. A Phase 1/2 clinical study WebDuoBody-PD-L1×4-1BB dose-dependently enhanced T-cell proliferation and pro-inflammatory cytokine production in vitro (e.g. IFNγ and TNFα; in polyclonal and antigen …
National Center for Biotechnology Information
WebDuoBody Based on the natural process of the Fab arm exchange of human IgG4 isotype in human serum, DuoBody was developed by Genmab in 2010 to overtake the mispairing of HC/HC heterodimer of BsAbs. A single matched point mutation at the interface of CH3-CH3 was introduced to prevent the HC/HC mispairing. WebDec 7, 2024 · Talquetamab, a DuoBody® IgG4 PAA binding antibody, showed evidence of a high response rate while maintaining a tolerable safety profile for patients heavily pretreated with relapsed/refractory multiple myeloma, according to early data presented during the 2024 ASH Annual Meeting & Exposition. iptg toxicity human
561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior …
WebDuffy blood group system, classification of human blood based on the presence of glycoproteins known as Fy antigens on the surface of red blood cells, endothelial cells … WebNov 12, 2024 · The DuoBody ® -CD3x5T4 (GEN1044) was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and … WebOct 14, 2024 · Media Release Copenhagen, Denmark, October 14, 2024 Preliminary data from Phase 1/2a trial of DuoBody®-PD-L1x4-1BB (GEN1046) in patients with... iptg working concentration